Clinical Study on the Effect of PTH on CYP3A4 Activity
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Know the risks and potential benefits of clinical studies and talk to your health care provider before participating.
Read our disclaimer for details.
Parathyroid hormone (PTH) may play an important role in the down-regulation of CYP3A4 expression induced by Chronic kidney diseases (CKD). In the study of molecular mechanism, the research group found that the expression of CYP3A2 metabolic enzyme in rat liver decreased in the state of CKD.And PTH may down-regulate the expression of CYP3A4 metabolic enzyme by inhibiting the expression of Nuclear factor- Kilobuse (NF-kB) p65 subunit
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Layout table for eligibility information
Ages Eligible for Study:
18 Years and older (Adult, Older Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Chronic renal function associated with hypertension
Chinese male or female subjects with an age of 18 or older were included;
The clinical physician diagnosed CKD with hypertension;
The physician decided that nifedipine controlled release tablets should be given.
Subjects agree to the study protocol, clinical and follow-up time, and sign the informed consent after the approval of the ethics committee;
Subjects will be able to communicate well with the investigator and will be able to complete the study as required.
Patients with CKD requiring dialysis treatment;
Other clinical reasons that may be considered inappropriate for inclusion by clinicians.